Rh factor: prevention of isoimmunization and clinical trial on mothers.
The results on the use of gammaG-immunoglobulin to Rh factor for the prevention of active immunization of Rh-negative mothers at risk appear most promising. One hundred and seven mothers in the clinical trial have been followed for periods of about 6 months to 1(1/2)12 years after delivery. Of these, 48 were treated mothers who received 5 ml gammaG-immunoglobulin to Rh, and 59 were untreated mothers. Of the 48 treated mothers none are actively immunized; seven of the 59 control mothers have become actively immunized to Rh.